Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML-Reference-Cited by-同舟云学术

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Published:2019-08-02 Issue:1 Volume:10 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Oellerich Thomas,Schneider Constanze,Thomas Dominique,Knecht Kirsten M.^ORCID,Buzovetsky Olga,Kaderali Lars,Schliemann Christoph,Bohnenberger Hanibal^ORCID,Angenendt Linus^ORCID,Hartmann Wolfgang^ORCID,Wardelmann Eva^ORCID,Rothenburger Tamara,Mohr Sebastian,Scheich Sebastian^ORCID,Comoglio Federico^ORCID,Wilke Anne,Ströbel Philipp,Serve Hubert^ORCID,Michaelis Martin^ORCID,Ferreirós Nerea,Geisslinger Gerd,Xiong Yong,Keppler Oliver T.,Cinatl Jindrich^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-019-11413-4.pdf

Reference64 articles.

1. Dombret, H. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126, 291–299 (2015).

2. Kantarjian, H. M. et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 30, 2670–2677 (2012).

3. Stahl, M. et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2, 923–932 (2018).

4. Silverman, L. R. et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 24, 3895–3903 (2006).

5. Bohl, S. R., Bullinger, L. & Rucker, F. G. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Rev. Hematol. 11, 361–371 (2018).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Vpx virus-like particles to improve cytarabine treatment response against acute myeloid leukemia;Clinical and Experimental Medicine;2024-07-13

2. The type of DNA damage response after decitabine treatment depends on the level of DNMT activity;Life Science Alliance;2024-06-21

3. Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS;The EMBO Journal;2024-05-17

4. Platform-directed allostery and quaternary structure dynamics of SAMHD1 catalysis;Nature Communications;2024-05-06

5. Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel;iScience;2024-02